Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Commentary|Videos|May 5, 2024
Dr Kutikov on Therapeutic Approaches in Urothelial Cancer Requiring Cystectomy
Author(s)Alexander Kutikov, MD, FACS
Alexander Kutikov, MD, FACS, discusses treatment options for patients with urothelial cancer requiring cystectomy.
Advertisement
Alexander Kutikov, MD, FACS, chair and professor, Department of Urology and the Roberta R. Scheller Chair in Urologic Oncology at Fox Chase Cancer Center, discusses treatment options for patients with urothelial cancer requiring cystectomy.
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has approved pembrolizumab plus enfortumab vedotin in MIBC.
Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
3
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
4
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
5